Published Khavinson group studies have not reported significant adverse events. Independent safety data are sparse. Peptide-class safety concerns (injection site reactions, potential immunogenicity) apply generically. The absence of reported toxicity in existing literature is not the same as an established safety profile from multi-centre trial data.

Spoke 6.6 · Sleep & Circadian Peptides

Epitalon and circadian rhythm: the pineal clock, melatonin normalisation, and an evidence base that requires honest scrutiny.

Q: Is Epitalon the same as melatonin?

No. Melatonin is a monoamine neurohormone secreted by the pineal gland. Epitalon is a synthetic tetrapeptide proposed to restore the pineal gland's capacity to synthesise melatonin. Exogenous melatonin delivers the hormone directly; Epitalon's claimed mechanism is upstream restoration of pineal output.

Q: Does Epitalon actually increase melatonin?

The Korkushko et al. (2003) paper reports normalisation of melatonin circadian profiles in elderly subjects after Epitalon. This is published indexed data. No independent research group has replicated this in a pre-registered trial with blinded outcome assessment as of April 2026.

Q: How does Epitalon compare to melatonin for circadian rhythm disruption?

Melatonin is incomparably better evidenced. Dozens of independent RCTs exist for jet lag, shift work disorder, and DSWPD; melatonin is approved as a medication in multiple jurisdictions. Epitalon's circadian data consists of a small number of studies from a single group. Melatonin is the appropriate evidence-graded consideration for circadian disruption.

By PeptideRadar Research Desk · April 18, 2026

CompoundEpitalon (Ala-Glu-Asp-Gly, tetrapeptide) MW~390 Da OriginKhavinson group, St. Petersburg, 1980s Proposed effectPineal restoration → melatonin normalisation Updated2026-04-18

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology as part of a decades-long programme of "peptide bioregulators." Its proposed circadian mechanism — restoration of pineal transcriptional activity and consequent melatonin normalisation in older adults — is biologically coherent and supported by published data. The limitation that any rigorous reader must hold in mind: virtually all of that data originates from a single research group, has not been replicated in pre-registered Western trials, and cannot yet be considered established by the standards used to evaluate approved therapeutics. This spoke covers the circadian-specific evidence; the broader longevity and anti-aging profile is covered in the Pillar 3 Epitalon overview.

Key points

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived conceptually from pineal gland extract. Developed by Khavinson's group in the 1980s–1990s.
The pineal gland produces melatonin; melatonin production declines with age. Age-related circadian rhythm disruption is a clinically significant problem with consequences for sleep, immune function, and metabolism.
The proposed Epitalon mechanism: the tetrapeptide binds to pineal cell DNA (specifically to chromatin) and restores transcriptional activity of genes involved in melatonin synthesis, normalising output in aged glands.
Khavinson group data (Korkushko et al., 2003; Khavinson et al., 2001) show melatonin profile normalisation in elderly subjects following Epitalon administration. These results have been published in peer-reviewed journals.
Independent Western replication: absent as of April 2026. No pre-registered RCT with circadian or sleep primary endpoints has been published outside Russia.
Regulatory status: Epitalon is not approved as a drug in any Western jurisdiction. It is available as a research chemical under RUO framing.

The pineal gland and the aging circadian clock

The suprachiasmatic nucleus (SCN) of the hypothalamus is the master circadian pacemaker. It synchronises biological clocks across peripheral tissues through multiple signals; melatonin, secreted by the pineal gland during darkness, is one of the primary output hormones that translates SCN timing into systemic circadian signals. Melatonin's amplitude and nocturnal peak are the key variables for circadian entrainment: high-amplitude nocturnal melatonin signals a strong circadian cue; low-amplitude flattened secretion produces circadian disruption.

The age-related decline in melatonin is well documented. Reiter (1992, Bioessays) reviewed the evidence showing progressive reduction in pineal melatonin synthesis from mid-adulthood, with a steeper decline after approximately age 50–60. By age 70–80, nocturnal melatonin amplitude may be only 25–50% of young-adult levels in some individuals. This decline correlates with the prevalence of sleep disruption, circadian phase advance, and subjective poor-sleep complaints in older populations.

The Pierpaoli and Regelson work (1994, PNAS) on melatonin and pineal function in aging mouse models established that pineal function is mechanistically linked to aging trajectories — the "pineal clock" concept. Whether this relationship is causal, coincident, or downstream of other aging processes remains debated. It provides, however, the biological framework within which Epitalon's pineal mechanism claim sits.

Epitalon's proposed mechanism: pineal transcriptional restoration

The Khavinson group's mechanistic proposal for Epitalon is that the tetrapeptide sequence Ala-Glu-Asp-Gly acts as a "peptide bioregulator" — a class of short peptides they propose can regulate gene transcription by interacting with specific DNA sequences. In the context of the pineal gland, the proposal is that Epitalon binds to chromatin regulatory elements in pinealocytes and restores transcription of genes involved in serotonin N-acetyltransferase (AANAT) activity — the rate-limiting step in melatonin synthesis.

If this mechanism is correct, Epitalon would not directly supply melatonin (unlike exogenous melatonin supplementation) but would restore the pineal gland's endogenous capacity to produce it, potentially normalising circadian amplitude more physiologically than supplementation. This distinction — restoration versus replacement — is central to the Khavinson group's framing of Epitalon as a bioregulator rather than a hormone replacement.

On the "DNA-binding peptide" mechanism The broader Khavinson programme of peptide bioregulators is built around the concept that short peptides can regulate gene transcription via chromatin interaction. This is a non-mainstream mechanistic proposal. Short peptides can interact with DNA in vitro; whether such interactions meaningfully alter transcription in intact cells, and whether the effect is gene-specific rather than non-selective, requires rigorous demonstration. The mechanism is plausible but not established in the canonical sense of molecular pharmacology.

The published human data: what Korkushko and Khavinson showed

Two papers from the Khavinson group provide the primary human circadian data for Epitalon:

Khavinson et al. (Neuroendocrinol Lett, 2001;22(4):251–254) reported on peptide regulation of melatonin production in the pineal gland, describing mechanisms by which pineal peptides including Epitalon's parent compound (Epithalamin) modulate melatonin synthesis in aged animals and humans.

Korkushko OV et al. (Neuroendocrinol Lett, 2003;24(3–4):245–247) reported a normalising effect of Epitalon on the circadian profile of melatonin in elderly subjects. The study measured serum melatonin over 24-hour profiles before and after Epitalon administration in elderly patients with disrupted circadian melatonin profiles. Post-treatment profiles showed higher nocturnal amplitudes and patterns more consistent with younger-adult melatonin profiles.

These are real studies published in indexed journals. The findings — if they replicate — would be clinically meaningful. The question for any reader applying Western evidence standards is: can a finding from a single research group in a single country, without independent pre-registered replication, be considered established? The honest answer is no, and this is not a dismissal of the work but an accurate statement of where it sits in the evidence hierarchy.

For comparison: the melatonin literature that supports its use for circadian rhythm disorders (jet lag, shift work disorder, delayed sleep-wake phase disorder) includes multiple independent groups, multiple countries, pre-registered trials, and regulatory approval in the EU and other jurisdictions. Epitalon's circadian evidence is at an earlier stage than melatonin by a significant margin.

The independent replication gap: what it means in practice

Science advances through replication by independent groups. When a finding is consistent across multiple labs with different equipment, different subject populations, and different incentive structures, confidence in that finding grows substantially. The absence of independent replication for Epitalon's circadian effects does not mean those effects are spurious — it means we cannot determine whether they are real at the confidence level required for clinical applications.

Three specific concerns that independent replication would address:

Outcome measurement standardisation. Melatonin assays vary in sensitivity and specificity. Findings reported using a single lab's assay system may not be directly comparable to findings using different commercial kits or methods.
Subject selection and blinding. Elderly subjects with disrupted melatonin profiles who are enrolled in a treatment study by the group that developed the treatment face potential selection and expectation effects. Independent groups with pre-specified inclusion criteria and blinded outcome assessment provide stronger protection against these biases.
Dose-response characterisation. The doses used in Khavinson group studies (typically 10 mg injections) have not been independently validated; optimal dosing for a circadian effect, if real, would require dose-ranging studies.

Epitalon and telomere biology: the adjacent longevity claim

Separate from the circadian mechanism, Epitalon has been associated with telomerase activation in some in vitro studies. Anisimov et al. (2004) showed lifespan extension in Drosophila; Khavinson and Morozov (2003) reviewed peptide bioregulator effects on human longevity markers. These findings are covered in the Pillar 3 Epitalon overview, which handles the full longevity, anti-aging, and telomere biology framing. This spoke intentionally restricts to the circadian and sleep-related evidence only.

How this fits in the Sleep & Circadian cluster

Within the Sleep & Circadian pillar, Epitalon occupies the "circadian and pineal regulator" family alongside Pinealon and VIP. Its position in the evidence hierarchy is between DSIP (which lacks even a confirmed receptor) and MK-677 (which has two PSG-confirmed human studies). Epitalon has human melatonin data but from a geographically concentrated single-group source without independent replication.

Related spoke connections within this cluster:

DSIP deep-dive spoke (6.1): comparison point for circadian vs. direct sleep-induction evidence
Peptides for jet lag spoke (6.8): where Epitalon's circadian-resetting rationale most directly applies
Peptides for shift workers (6.10): same circadian disruption context
Pinealon for sleep spoke (6.22): the companion Khavinson-group bioregulator with analogous evidence structure
Circadian disruption and peptide therapy spoke (6.26): the broader landscape
Epitalon cycle protocol spoke (Pillar 3, 3.28): practical dosing and cycling framework

Where to read further

Primary and review references, current to 2026-04:

Khavinson VKh, et al. "Peptide regulation of melatonin production in the pineal gland." Neuroendocrinol Lett. 2001;22(4):251–254.
Korkushko OV, et al. "Normalising effect of Epitalon on the circadian profile of melatonin in elderly subjects." Neuroendocrinol Lett. 2003;24(3–4):245–247.
Khavinson VKh, Morozov VG. "Peptides of pineal gland and thymus prolong human life." Neuro Endocrinol Lett. 2003;24(3–4):233–240.
Anisimov VN, et al. "Effect of Epitalon on the lifespan increase in Drosophila melanogaster." Mech Ageing Dev. 2004;125(10–11):741–749.
Reiter RJ. "The aging pineal gland and its physiological consequences." Bioessays. 1992;14(3):169–175.
Pierpaoli W, Regelson W. "Pineal control of aging: effect of melatonin and pineal grafting on aging mice." Proc Natl Acad Sci USA. 1994;91(2):787–791.
Anisimov VN, Khavinson VKh. "Peptide bioregulators inhibit tumor development." Crit Rev Oncol Hematol. 2010;74(3):214–225.

Frequently asked

Is Epitalon the same as melatonin?

No. Melatonin is a monoamine neurohormone (N-acetyl-5-methoxytryptamine) synthesised from serotonin in the pineal gland and secreted nocturnally as a circadian signal. Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) proposed to restore the pineal gland's capacity to synthesise melatonin. Exogenous melatonin bypasses the pineal gland to deliver the hormone directly; Epitalon's claimed mechanism is upstream — restoring the gland's endogenous output. This distinction is theoretically important but has not been validated by independent clinical trials.

Does Epitalon actually increase melatonin?

The Korkushko et al. (2003) paper from the Khavinson group reports normalisation of melatonin circadian profiles in elderly subjects after Epitalon administration. This is published data in an indexed journal. The limitation is that no independent research group has replicated this finding in a pre-registered trial with blinded outcome assessment. The data are real and worth knowing; the confidence level is lower than for independently replicated findings.

Why is the Epitalon evidence concentrated in Russian research?

Epitalon was developed within the Soviet and post-Soviet Russian gerontology research infrastructure, specifically at the St. Petersburg Institute of Bioregulation and Gerontology. The compound has not been adopted by major Western pharmaceutical companies for clinical development. This is partly because the mechanism (peptide bioregulator acting on chromatin) is outside mainstream Western pharmacology paradigms, and partly because the gerontology indication does not have a clear regulatory pathway. The geographic concentration of the evidence is a consequence of these structural factors, not necessarily a marker of scientific fraud — but it does limit the confidence that can be placed in unreplicated findings.

How does Epitalon compare to melatonin for circadian rhythm disruption?

Melatonin is incomparably better evidenced for circadian applications. Melatonin has dozens of independent RCTs for jet lag, shift work disorder, and delayed sleep-wake phase disorder, and is approved as a medication in multiple jurisdictions. Epitalon's circadian data consists of a small number of studies from a single group. If you need an evidence-graded recommendation for circadian rhythm disruption, melatonin is the appropriate first-line consideration based on existing evidence. Epitalon's theoretical advantage — upstream pineal restoration vs. exogenous hormone delivery — has not been validated against melatonin in a head-to-head study.

Is Epitalon safe?

Safety data for Epitalon come primarily from the Khavinson group's studies, which have not reported significant adverse events in published literature. Independent safety data are sparse. For a tetrapeptide of this size, peptide-class safety concerns — local injection site reactions if injected, potential immunogenicity — apply generically. The absence of reported toxicity in the existing literature is not the same as an established safety profile validated through multi-centre trial data. Our Pillar 3 Epitalon overview covers the available safety literature in more detail.

Reviewer sign-off Reviewed 2026-04-18 by the PeptideRadar Research Desk. This spoke covers Epitalon's circadian and melatonin-specific evidence only. The longevity, anti-aging, and telomere biology framing is covered in the Pillar 3 Epitalon overview (epitalon.html). The evidence grading for Epitalon's circadian effects: human data exist from the Khavinson group; independent replication is absent as of April 2026. This article does not imply clinical efficacy or fitness for human use. Corrections policy: errors flagged in a dated note, not silently edited. Contact: corrections@peptideradar.net.